Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

The Arrows and Colors Cognitive Test (ACCT): A new verbal-motor free cognitive measure for executive functions in ALS.

Poletti B, Carelli L, Faini A, Solca F, Meriggi P, Lafronza A, Ciringione L, Pedroli E, Ticozzi N, Ciammola A, Cipresso P, Riva G, Silani V.

PLoS One. 2018 Aug 9;13(8):e0200953. doi: 10.1371/journal.pone.0200953. eCollection 2018.

2.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC.

JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775.

PMID:
29902295
3.

Cognitive-behavioral longitudinal assessment in ALS: the Italian Edinburgh Cognitive and Behavioral ALS screen (ECAS).

Poletti B, Solca F, Carelli L, Faini A, Madotto F, Lafronza A, Monti A, Zago S, Ciammola A, Ratti A, Ticozzi N, Abrahams S, Silani V.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):387-395. doi: 10.1080/21678421.2018.1473443. Epub 2018 May 26.

PMID:
29804470
4.

The Complex Interplay Between Depression/Anxiety and Executive Functioning: Insights From the ECAS in a Large ALS Population.

Carelli L, Solca F, Faini A, Madotto F, Lafronza A, Monti A, Zago S, Doretti A, Ciammola A, Ticozzi N, Silani V, Poletti B.

Front Psychol. 2018 Apr 5;9:450. doi: 10.3389/fpsyg.2018.00450. eCollection 2018.

5.

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.

Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels JH.

Ann Oncol. 2017 Oct 1;28(10):2526-2532. doi: 10.1093/annonc/mdx344.

6.

Brain-Computer Interface for Clinical Purposes: Cognitive Assessment and Rehabilitation.

Carelli L, Solca F, Faini A, Meriggi P, Sangalli D, Cipresso P, Riva G, Ticozzi N, Ciammola A, Silani V, Poletti B.

Biomed Res Int. 2017;2017:1695290. doi: 10.1155/2017/1695290. Epub 2017 Aug 23. Review.

7.

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A.

Lung Cancer. 2017 Jul;109:101-108. doi: 10.1016/j.lungcan.2017.05.010. Epub 2017 May 11.

8.

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).

Codony-Servat C, Codony-Servat J, Karachaliou N, Molina MA, Chaib I, Ramirez JL, de Los Llanos Gil M, Solca F, Bivona TG, Rosell R.

Oncotarget. 2017 Jul 18;8(29):47305-47316. doi: 10.18632/oncotarget.17625.

9.

An eye-tracker controlled cognitive battery: overcoming verbal-motor limitations in ALS.

Poletti B, Carelli L, Solca F, Lafronza A, Pedroli E, Faini A, Ticozzi N, Ciammola A, Meriggi P, Cipresso P, Lulé D, Ludolph AC, Riva G, Silani V.

J Neurol. 2017 Jun;264(6):1136-1145. doi: 10.1007/s00415-017-8506-z. Epub 2017 May 13.

PMID:
28503706
10.

Cognitive-constructivist Approach in Medical Settings: The Use of Personal Meaning Questionnaire for Neurological Patients' Personality Investigation.

Poletti B, Carelli L, Lafronza A, Solca F, Faini A, Ciammola A, Grobberio M, Raimondi V, Pezzati R, Ardito RB, Silani V.

Front Psychol. 2017 Apr 11;8:582. doi: 10.3389/fpsyg.2017.00582. eCollection 2017.

11.

Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis.

Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, O'Raw A, Cook C, Pregent L, Belzil V, van Blitterswijk M, Tabassian LJ, Lee CW, Yue M, Tong J, Song Y, Castanedes-Casey M, Rousseau L, Phillips V, Dickson DW, Rademakers R, Fryer JD, Rush BK, Pedraza O, Caputo AM, Desaro P, Palmucci C, Robertson A, Heckman MG, Diehl NN, Wiggs E, Tierney M, Braun L, Farren J, Lacomis D, Ladha S, Fournier CN, McCluskey LF, Elman LB, Toledo JB, McBride JD, Tiloca C, Morelli C, Poletti B, Solca F, Prelle A, Wuu J, Jockel-Balsarotti J, Rigo F, Ambrose C, Datta A, Yang W, Raitcheva D, Antognetti G, McCampbell A, Van Swieten JC, Miller BL, Boxer AL, Brown RH, Bowser R, Miller TM, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Traynor BJ, Disney MD, Benatar M, Silani V, Glass JD, Floeter MK, Rothstein JD, Boylan KB, Petrucelli L.

Sci Transl Med. 2017 Mar 29;9(383). pii: eaai7866. doi: 10.1126/scitranslmed.aai7866.

12.

Non-reproducible sequence artifacts in FFPE tissue: an experience report.

Ofner R, Ritter C, Ugurel S, Cerroni L, Stiller M, Bogenrieder T, Solca F, Schrama D, Becker JC.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1199-1207. doi: 10.1007/s00432-017-2399-1. Epub 2017 Mar 17.

PMID:
28314930
13.

An eye-tracking controlled neuropsychological battery for cognitive assessment in neurological diseases.

Poletti B, Carelli L, Solca F, Lafronza A, Pedroli E, Faini A, Zago S, Ticozzi N, Ciammola A, Morelli C, Meriggi P, Cipresso P, Lulé D, Ludolph AC, Riva G, Silani V.

Neurol Sci. 2017 Apr;38(4):595-603. doi: 10.1007/s10072-016-2807-3. Epub 2017 Jan 11.

PMID:
28078566
14.

Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.

Sini P, Gürtler U, Zahn SK, Baumann C, Rudolph D, Baumgartinger R, Strauss E, Haslinger C, Tontsch-Grunt U, Waizenegger IC, Solca F, Bader G, Zoephel A, Treu M, Reiser U, Garin-Chesa P, Boehmelt G, Kraut N, Quant J, Adolf GR.

Mol Cancer Ther. 2016 Oct;15(10):2388-2398. Epub 2016 Aug 5.

15.

The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS).

Poletti B, Solca F, Carelli L, Madotto F, Lafronza A, Faini A, Monti A, Zago S, Calini D, Tiloca C, Doretti A, Verde F, Ratti A, Ticozzi N, Abrahams S, Silani V.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct - Nov;17(7-8):489-498. Epub 2016 May 24.

PMID:
27219526
16.

Cognitive assessment in Amyotrophic Lateral Sclerosis by means of P300-Brain Computer Interface: a preliminary study.

Poletti B, Carelli L, Solca F, Lafronza A, Pedroli E, Faini A, Zago S, Ticozzi N, Meriggi P, Cipresso P, Lulé D, Ludolph AC, Riva G, Silani V.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct - Nov;17(7-8):473-481. Epub 2016 May 12.

PMID:
27169693
17.

Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.

Ioannou N, Seddon AM, Dalgleish A, Mackintosh D, Solca F, Modjtahedi H.

Int J Oncol. 2016 Mar;48(3):908-18. doi: 10.3892/ijo.2016.3320. Epub 2016 Jan 5.

18.

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.

Alshami J, Guiot MC, Owen S, Kavan P, Gibson N, Solca F, Cseh A, Reardon DA, Muanza T.

Oncotarget. 2015 Oct 20;6(32):34030-7. doi: 10.18632/oncotarget.5297.

19.

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R, Solca F, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J, Spicer J.

Eur J Cancer. 2015 Nov;51(16):2275-84. doi: 10.1016/j.ejca.2015.07.041. Epub 2015 Aug 18.

PMID:
26296295
20.

Counterfactual Thinking Deficit in Huntington's Disease.

Solca F, Poletti B, Zago S, Crespi C, Sassone F, Lafronza A, Maraschi AM, Sassone J, Silani V, Ciammola A.

PLoS One. 2015 Jun 12;10(6):e0126773. doi: 10.1371/journal.pone.0126773. eCollection 2015.

21.

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice.

Slobbe P, Windhorst AD, Stigter-van Walsum M, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ.

EJNMMI Res. 2015 Mar 20;5:14. doi: 10.1186/s13550-015-0088-0. eCollection 2015.

22.

Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.

Young NR, Soneru C, Liu J, Grushko TA, Hardeman A, Olopade OI, Baum A, Solca F, Cohen EE.

Target Oncol. 2015 Dec;10(4):501-8. doi: 10.1007/s11523-014-0353-6. Epub 2015 Jan 6.

23.

A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.

Rimawi MF, Aleixo SB, Rozas AA, Nunes de Matos Neto J, Caleffi M, Figueira AC, Souza SC, Reiriz AB, Gutierrez C, Arantes H, Uttenreuther-Fischer MM, Solca F, Osborne CK.

Clin Breast Cancer. 2015 Apr;15(2):101-9. doi: 10.1016/j.clbc.2014.11.004. Epub 2014 Nov 15.

PMID:
25537159
24.

Counterfactual thinking in Tourette's syndrome: a study using three measures.

Zago S, Delli Ponti A, Mastroianni S, Solca F, Tomasini E, Poletti B, Inglese S, Sartori G, Porta M.

Behav Neurol. 2014;2014:256089. doi: 10.1155/2014/256089. Epub 2014 Nov 30.

25.

Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors.

Slobbe P, Windhorst AD, Stigter-van Walsum M, Schuit RC, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ.

Nucl Med Biol. 2014 Oct;41(9):749-57. doi: 10.1016/j.nucmedbio.2014.06.005. Epub 2014 Jun 25.

PMID:
25066021
26.

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.

Modjtahedi H, Cho BC, Michel MC, Solca F.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Jun;387(6):505-21. doi: 10.1007/s00210-014-0967-3. Epub 2014 Mar 19. Review.

27.

Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.

Harbeck N, Solca F, Gauler TC.

Future Oncol. 2014 Jan;10(1):21-40. doi: 10.2217/fon.13.244.

PMID:
24328407
28.

Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation.

Kim SM, Yun MR, Hong YK, Solca F, Kim JH, Kim HJ, Cho BC.

Mol Cancer Ther. 2013 Oct;12(10):2145-56. doi: 10.1158/1535-7163.MCT-12-1188. Epub 2013 Jul 24.

29.

The use of P300-based BCIs in amyotrophic lateral sclerosis: from augmentative and alternative communication to cognitive assessment.

Cipresso P, Carelli L, Solca F, Meazzi D, Meriggi P, Poletti B, Lulé D, Ludolph AC, Silani V, Riva G.

Brain Behav. 2012 Jul;2(4):479-98. doi: 10.1002/brb3.57.

30.

Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.

Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, Soo RA, Christensen JG, Lee JH, Cho BC.

Mol Cancer Ther. 2012 Oct;11(10):2254-64. doi: 10.1158/1535-7163.MCT-12-0311. Epub 2012 Aug 13.

31.

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR.

J Pharmacol Exp Ther. 2012 Nov;343(2):342-50. doi: 10.1124/jpet.112.197756. Epub 2012 Aug 10.

32.

Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells.

Eberl M, Klingler S, Mangelberger D, Loipetzberger A, Damhofer H, Zoidl K, Schnidar H, Hache H, Bauer HC, Solca F, Hauser-Kronberger C, Ermilov AN, Verhaegen ME, Bichakjian CK, Dlugosz AA, Nietfeld W, Sibilia M, Lehrach H, Wierling C, Aberger F.

EMBO Mol Med. 2012 Mar;4(3):218-33. doi: 10.1002/emmm.201100201. Epub 2012 Feb 1.

33.

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.

Ioannou N, Dalgleish AG, Seddon AM, Mackintosh D, Guertler U, Solca F, Modjtahedi H.

Br J Cancer. 2011 Nov 8;105(10):1554-62. doi: 10.1038/bjc.2011.396. Epub 2011 Oct 4.

34.

Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.

Kim SM, Kim JS, Kim JH, Yun CO, Kim EM, Kim HK, Solca F, Choi SY, Cho BC.

Cancer Lett. 2010 Oct 28;296(2):150-9. doi: 10.1016/j.canlet.2010.04.006. Epub 2010 May 4.

PMID:
20444542
35.

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.

Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II, Wong KK.

Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):474-9. doi: 10.1073/pnas.0808930106. Epub 2009 Jan 2.

36.

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK.

Oncogene. 2008 Aug 7;27(34):4702-11. doi: 10.1038/onc.2008.109. Epub 2008 Apr 14.

37.

Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma.

Schütze C, Dörfler A, Eicheler W, Zips D, Hering S, Solca F, Baumann M, Krause M.

Strahlenther Onkol. 2007 May;183(5):256-64.

PMID:
17497097
38.

Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.

Solca FF, Baum A, Langkopf E, Dahmann G, Heider KH, Himmelsbach F, van Meel JC.

J Pharmacol Exp Ther. 2004 Nov;311(2):502-9. Epub 2004 Jun 15.

39.
40.

A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity.

Stratowa C, Baum A, Castañon MJ, Dahmann G, Himmelsbach F, Himmler A, Loeber G, Metz T, Schnitzer R, Solca F, Spevak W, Tontsch U, von Rüden T.

Anticancer Drug Des. 1999 Oct;14(5):393-402.

PMID:
10766294
41.

Inhibition of MAP kinase by sphingosine and its methylated derivative, N,N-dimethylsphingosine.

Sakakura C, Sweeney E, Shirahama T, Ruan F, Solca F, Kohno M, Hakomori S, Fischer E, Igarashi Y.

Int J Oncol. 1997 Jul;11(1):31-9.

PMID:
21528177
42.

Cloning and characterization of rat density-enhanced phosphatase-1, a protein tyrosine phosphatase expressed by vascular cells.

Borges LG, Seifert RA, Grant FJ, Hart CE, Disteche CM, Edelhoff S, Solca FF, Lieberman MA, Lindner V, Fischer EH, Lok S, Bowen-Pope DF.

Circ Res. 1996 Sep;79(3):570-80.

PMID:
8781490
43.

Identification and purification of a chicken brain neuroglia-associated protein.

Solca FF, Lurie DI, Diltz CD, Johnson RS, Kumar S, Rubel EW, Fischer EH.

J Biol Chem. 1994 Nov 4;269(44):27559-65.

44.

Receptors for melanocyte-stimulating hormone on melanoma cells.

Eberle AN, Siegrist W, Bagutti C, Chluba-De Tapia J, Solca F, Wikberg JE, Chhajlani V.

Ann N Y Acad Sci. 1993 May 31;680:320-41. Review. No abstract available.

PMID:
8390156
45.

A general peptide substrate for protein tyrosine phosphatases.

Daum G, Solca F, Diltz CD, Zhao Z, Cool DE, Fischer EH.

Anal Biochem. 1993 May 15;211(1):50-4.

PMID:
8323038
46.

B16-G4F mouse melanoma cells: an MSH receptor-deficient cell clone.

Solca FF, Chluba-de Tapia J, Iwata K, Eberle AN.

FEBS Lett. 1993 May 10;322(2):177-80.

47.

MSH receptors on mouse and human melanoma cells: receptor identification, analysis and quantification.

Siegrist W, Bagutti C, Solca F, Girard J, Eberle AN.

Prog Histochem Cytochem. 1992;26(1-4):110-8. No abstract available.

PMID:
1336609
48.

Heterogeneity of the MSH receptor among B16 murine melanoma subclones.

Solcà FF, Salomon Y, Eberle AN.

J Recept Res. 1991;11(1-4):379-90.

PMID:
1653343
49.

Biologically active monoiodinated alpha-MSH derivatives for receptor binding studies using human melanoma cells.

Eberle AN, Verin VJ, Solca F, Siegrist W, Küenlin C, Bagutti C, Stutz S, Girard J.

J Recept Res. 1991;11(1-4):311-22.

PMID:
1653337
50.

Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells.

Siegrist W, Solca F, Stutz S, Giuffrè L, Carrel S, Girard J, Eberle AN.

Cancer Res. 1989 Nov 15;49(22):6352-8.

Supplemental Content

Support Center